Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Restricted cubic spline regression model depicting the association between serum vitamin D (VitD) levels and the odds of ruptured intracranial aneurysms.

Source: Associations of Vitamin D With IA Rupture in the Observational Study. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Genetic instrumental-variable study.

Genetic instrumental-variable study

Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Serum Vitamin D Levels Were Not Associated With the Risk of Aneurysmal Subarachnoid Hemorrhage: A Large Cohort Study With Propensity Score Matching and Mendelian Randomization Analysis

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Serum Vitamin D Levels Were Not Associated With the Risk of Aneurysmal Subarachnoid Hemorrhage: A Large Cohort Study With Propensity Score Matching and Mendelian Randomization Analysis

Genetic instrumental-variable study · CNS Neuroscience & Therapeutics · 2025

Original publication title

Serum Vitamin D Levels Were Not Associated With the Risk of Aneurysmal Subarachnoid Hemorrhage: A Large Cohort Study With Propensity Score Matching and Mendelian Randomization Analysis

Haoran Qiu; Kai Chen; Yang Yu; Ziyin Song; Jingzheng Liu; Lvyin Luo; Xinlong Ma; Zhaoyang Yuan; Maogui Li; Jianfeng Zhuang; Mingxiang Zhang; Wandong Su; Yunyan Wang; Donghai Wang; Weiying Zhong

© 2025 The Author(s). CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our study did not demonstrate an association or a causal relationship between VitD levels and aneurysmal subarachnoid hemorrhage (aSAH). The inverse associations observed in previous cohort studies may be attributable to confounding factors or reverse causation. Although VitD deficiency is common in patients with aSAH, supplementation may not prevent aneurysm rupture.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Intracranial aneurysms (IAs) are abnormal dilations of the cerebral arterial wall, posing a significant health risk due to their potential rupture, which can cause subarachnoid hemorrhage (SAH), a life‐threatening condition with high morbidity and mortality [1]. Incidental IAs are increasingly diagnosed owing to the widespread use of noninvasive neuroimaging. However, not all unruptured IAs rupture during a patient’s lifetime. Clinical factors such as hypertension, smoking, history of SAH, as well as aneurysm size and location, have been associated with IA growth and rupture [2, 3].

Tools such as the ELAPSS and PHASES scores, which incorporate these factors, have been developed to predict the risk of IA growth and rupture [4, 5]. Nevertheless, the literature lacks appropriate hematological indices for predicting aneurysm rupture.

While the pathological mechanisms underlying IA rupture remain incompletely understood, factors such as inflammation, oxidative stress, hemodynamic stress, and genetic predispositions are considered contributing factors [2, 3]. Abnormal blood flow and shear stress may compromise vascular integrity, while inflammation and oxidative stress could further damage the aneurysm wall, thereby increasing the rupture risk [2, 3, 6]. Vitamin D (VitD), a fat‐soluble steroid vitamin essential for calcium homeostasis and immune regulation, may confer vascular health benefits due to its anti‐inflammatory and antioxidative properties [7, 8].

Low levels of VitD are associated with elevated vascular inflammation, oxidative stress, endothelial dysfunction, and increased risk of cardiovascular and cerebrovascular events, including hypertension, atherosclerosis, myocardial infarction, and stroke [7, 8, 9]. VitD deficiency is also prevalent among IA patients [10, 11]. However, its relationship with IA rupture remains unclear. One study reported an inverse correlation between VitD levels and the risk of aneurysmal subarachnoid hemorrhage (aSAH) [12], whereas another found no association [11].

These discrepancies may arise from variations in sample size, study populations, methodologies, or unaccounted confounders. Additionally, VitD deficiency could result from aneurysm rupture, suggesting potential reverse causality. Thus, the specific role of VitD in aSAH remains controversial, and further research is required to determine whether VitD deficiency is associated with IA rupture.

Therefore, in this study, a large case: control study with propensity score matching (PSM) to balance confounding factors was conducted to investigate the potential association between VitD levels and aSAH. However, observational studies remain vulnerable to unmeasured confounders. To address this limitation, we also performed a two‐sample Mendelian randomization (MR) analysis to explore potential causal relationships. By integrating these methods, this study aims to provide high‐quality evidence regarding the relationship between VitD status and aSAH. The findings may improve our understanding of IA rupture mechanisms.

Source: Introduction Source: Introduction Source: Introduction

Study methods

What methods does the paper describe?

2.1

Observational Study Design

This retrospective case: control study comprised consecutive patients with IA treated at Qilu Hospital of Shandong University between March 2018 and May 2021. The study was approved by the Ethics Committee of Qilu Hospital of Shandong University, and written informed consent was obtained from all participants prior to enrollment. All IAs were confirmed using computed tomography (CT), magnetic resonance imaging (MRI), or digital subtraction angiography (DSA). SAH was confirmed via CT scans. Ruptured IAs were defined as cases presenting with aneurysmal SAH, regardless of the number of aneurysms present, while unruptured IAs were defined as patients with at least one aneurysm and no history of SAH.

Exclusion criteria were as follows: (1) recent administration of VitD supplements or glucocorticoids within 1 month prior to the study; (2) concomitant vascular diseases, such as arteriovenous malformations, moyamoya disease, or arteriovenous fistulas; (3) recurrent, fusiform, traumatic, bacterial, or dissecting aneurysms; (4) aneurysmal SAH occurring more than 72 h before admission; (5) SAH of unknown etiology or non‐aneurysmal SAH; and (6) age < 18 years. Ultimately, 499 patients with either unruptured or ruptured IAs were included in the study. The study flowchart is presented in Figure 1A.

FIGURE 1

The flow chart of the present study.

Figure image at the original source: open the original paper. This file is not included in this text import.

The patients’ demographic characteristics, comorbidities (including diabetes mellitus, hypertension, and hyperlipidemia), and aneurysm characteristics (such as location and number) were recorded. For patients with multiple aneurysms, the study evaluated the location (anterior or posterior circulation) of the primary aneurysm treated during hospitalization. Fasting venous blood samples were collected within 24 h of admission to measure 25‐hydroxyvitamin D levels and conduct lipid profile tests, including triglycerides (TG), total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), and high‐density lipoprotein cholesterol (HDL‐C). Body mass index (BMI) was categorized as underweight (≤ 18.5 kg/m2), normal weight (18.5 to 24 kg/m2), overweight (24 to 28 kg/m2), or obese (> 28 kg/m2).

Hypertension was defined as a documented history of the condition (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg), irrespective of antihypertensive treatment. Diabetes mellitus was defined as patients receiving antidiabetic medication, a fasting glucose level ≥ 7 mmol/L from previous health assessments, or a hemoglobin A1c level ≥ 6.5%. Hyperlipidemia was defined as lipid‐lowering medication use or fasting plasma TC ≥ 6 mmol/L, TG ≥ 2 mmol/L, or LDL ≥ 3.5 mmol/L. Current smoking was defined as consumption of ≥ 5 cigarettes per day, and alcohol consumption as intake of ≥ 150 g per week.

VitD levels were categorized as deficient (< 20 ng/mL), insufficient (20 to 29 ng/mL), or normal (≥ 30 ng/mL).

Statistical analyses were performed using SPSS 25.0 (IBM Corp.). Continuous variables were expressed as mean ± standard deviation or median [interquartile range], depending on their distribution. The Shapiro: Wilk test was used to assess normality, with a p‐value < 0.05 indicating a deviation from normal distribution. Group comparisons were conducted using Student’s t‐test for normally distributed variables and the Mann: Whitney U test for non‐normally distributed variables. Categorical variables were expressed as frequencies and percentages and were compared using the χ 2 test or Fisher’s exact test.

Factors with p < 0.1 in univariate analysis were included in binary logistic regression analysis using an enter process to identify independent predictors. PSM was used to balance confounding factors between patients with and without aneurysmal SAH. A one‐to‐one PSM analysis using the nearest neighbor method with a caliper value of 0.01 was conducted to adjust for imbalanced factors. A restricted cubic spline (RCS) regression model was employed to examine potential linear or nonlinear associations between serum VitD levels and the risk of aSAH.

Four knots were positioned at the 5th, 35th, 65th, and 95th percentiles of the VitD distribution, with the median serving as the reference point. The RCS model was fitted using the “rms” package (version 6.8 to 2), and spline plots were generated using the “plotRCS” package (version 0.1.5) in R software (version 4.4.1). Statistical significance was defined as a two‐tailed p‐value < 0.05.

2.2

MR Analysis

A two‐sample MR analysis was performed to investigate the causal relationship between VitD levels and aSAH. Figure 1B shows the analysis flowchart.

Genetic instruments for VitD levels were obtained from genome‐wide association studies (GWAS) datasets available through the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/), a public resource for investigating genetic associations with complex traits. Summary‐level GWAS data on IAs were derived from two large cohorts: the discovery cohort, conducted by the International Stroke Genetics Consortium (ISGC) with individuals of European ancestry, and the replication cohort from FinnGen. The discovery cohort included 5140 ruptured cases, 2070 unruptured cases, and 71,934 controls, while the replication cohort had 6236 ruptured cases, 3014 unruptured cases, and 412,105 controls.

Additional details regarding the data sources used in this study are provided in File S1.

From these GWAS datasets, single nucleotide polymorphisms (SNPs) significantly associated with VitD levels (p < 5 × 10−8) were selected as candidate instrumental variables (IVs). Linkage disequilibrium (LD) analysis was conducted to ensure SNP independence, applying a threshold of LD‐r 2 < 0.001 and a clumping distance threshold of > 10,000 kb. The F‐statistic [F = R 2(N‐2)/(1‐R 2)] was calculated to evaluate IV strength, with SNPs failing to meet the criterion of F ≥ 10 excluded to mitigate weak instrument bias, thereby maintaining the robustness of the analysis.

The inverse variance‐weighted (IVW) method was employed as the primary approach for causal estimation, providing reliable results in the absence of heterogeneity or horizontal pleiotropy. Supplementary methods: including MR‐Egger regression, weighted median, simple mode, and weighted mode: were used to ensure robustness under varying conditions. Heterogeneity was assessed using Cochran’s Q test, and if heterogeneity was detected (p < 0.05), adjusted results were reanalyzed [13]. Horizontal pleiotropy was evaluated using the MR‐Egger intercept method, with p > 0.05 indicating no pleiotropy and supporting MR reliability [14].

The leave‐one‐out (LOO) method was applied to systematically exclude each SNP to assess result stability. All analyses were conducted using R software (version 4.4.1) with the “TwoSampleMR” package [15], with statistical significance defined as p < 0.05.

Source: Materials and Methods Source: Materials and Methods

Associations of Vitamin D With IA Rupture in the Observational Study

Results: Associations of Vitamin D With IA Rupture in the Observational Study

The baseline characteristics are presented in Table 1. A total of 499 patients with 619 IAs were included in this study, comprising 337 (67.5%) females and 162 (32.5%) males. The median age was 58.0 years [52.0, 64.0], and the median BMI was 24.8 kg/m2 [22.3, 27.3]. Among these patients, 184 (36.9%) had ruptured IAs, and 105 (21.0%) had multiple IAs.

TABLE 1

Baseline information of enrolled patients before or after propensity score matching (PSM).

CharacteristicBefore PSMAfter PSM
Overall (n = 499)Unruptured (n = 315)Ruptured (n = 184) p Overall (n = 224)Unruptured (n = 112)Ruptured (n = 112) p
Sex (Female)337 (67.5)215 (43.1)122 (24.4)0.654 a 157 (70.1)80 (35.7)77 (34.4)0.662 a
Age (year)0.026 a 0.774 a
≤ 50110 (22.0)58 (11.6)52 (10.4)43 (19.2)24 (10.7)19 (8.5)
51 to 60178 (35.7)110 (22.0)68 (13.6)85 (37.9)41 (18.3)44 (19.6)
61 to 70168 (33.7)118 (23.6)50 (10.0)78 (34.8)37 (16.5)41 (18.3)
> 7043 (8.6)29 (5.8)14 (2.8)18 (8.0)9 (7.3)10 (8.1)
BMI0.699 a 0.625 b
Underweight15 (3.0)9 (1.8)6 (1.2)7 (3.1)3 (1.3)4 (1.8)
Normal188 (37.9)114 (22.8)75 (15.0)89 (39.7)48 (21.4)41 (18.3)
Overweight204 (40.7)134 (26.9)69 (13.8)94 (42.0)47 (21.0)47 (21.0)
Obese92 (18.4)58 (11.6)34 (6.8)34 (15.2)14 (6.3)20 (8.9)
Smoking85 (17.0)50 (10.0)35 (7.0)0.367 a 36 (16.1)19 (8.5)17 (7.6)0.716 a
Drinking53 (10.6)29 (5.8)24 (4.8)0.180 a 25 (11.2)11 (4.9)14 (6.3)0.524 a
Diabetes70 (14.0)53 (10.6)17 (3.4)0.019 a 20 (8.9)9 (4.0)11 (4.9)0.639 a
Hypertension291 (58.3)184 (36.9)107 (21.4)0.955 a 132 (58.9)63 (28.1)69 (30.8)0.415 a
Hyperlipidemia142 (28.5)91 (18.2)51 (10.2)0.780 a 56 (25.0)28 (12.5)28 (12.5)1.000 a
Blood test dates0.147 a 0.885 a
Mar: May130 (26.1)81 (16.2)49 (9.8)60 (26.8)28 (12.5)32 (14.3)
Jun: Aug100 (20.0)57 (11.4)43 (8.6)45 (20.1)23 (10.3)22 (9.8)
Sep: Nov156 (31.3)96 (19.2)60 (12.0)73 (32.6)36 (16.1)37 (16.5)
Dec: Feb113 (22.6)81 (16.2)32 (6.4)46 (20.5)25 (11.2)21 (9.4)
Anterior circulating aneurysm477 (95.6)301 (60.3)176 (35.3)0.960 a 216 (96.4)110 (49.1)106 (47.3)0.280 a
Multiple aneurysms105 (21.0)56 (11.2)49 (9.8)0.019 a 45 (20.1)21 (9.4)24 (10.7)0.617 a
Vitamin D (ng/mL)17.0 [12.1 to 22.4]17.6 [12.6 to 22.6]16.3 [11.6 to 22.3]0.418 c 16.0 [11.5 to 21.3]15.8 [11.7 to 21.4]16.2 [10.8 to 21.2]0.904 c
Vitamin D levels0.339 a 0.947 a
Normal46 (9.2)26 (5.2)20 (4.0)22 (9.8)11 (4.9)11 (4.9)
Insufficient133 (26.7)90 (18.0)43 (8.6)48 (21.4)23 (10.3)25 (11.2)
Deficient320 (64.1)199 (39.9)121 (24.2)154 (68.8)78 (34.8)76 (33.9)

Note: Variables are presented as number of patients (%) or median (interquartile range), as appropriate.

a

p‐values calculated using Pearson’s chi‐square test.

b

p‐values calculated using Fisher’s exact test.

c

p‐values calculated using Mann: Whitney U test.

In this study, diabetes was inversely associated with the risk of aSAH (p = 0.034; odds ratio [OR], 0.53; 95% confidence interval [CI], 0.290 to 0.954), whereas multiple aneurysms increased the risk of aSAH (p = 0.006; OR, 1.88; 95% CI, 1.197 to 2.940) in multivariate analysis (Table S1). The prevalence of diabetes was 16.8% (53/315) in patients with unruptured IAs, compared with 9.2% (17/184) in patients with ruptured IAs. Conversely, multiple aneurysms were more prevalent in ruptured IA patients (26.6%, 49/184) than in unruptured IA patients (17.8%, 56/315).

Age, sex, BMI, smoking, alcohol use, hypertension, hyperlipidemia, and aneurysm location (anterior circulation) showed no significant association with aSAH in multivariate analysis (p > 0.05).

Blood test dates, as presented in Table 1, did not differ significantly between patients with unruptured IA and those with ruptured IA (p = 0.147). The median VitD level was 17.0 ng/mL [12.1 to 22.4]. VitD levels were normal in 9.2% of patients, insufficient in 26.7%, and deficient in 64.1% of patients. No significant difference in VitD levels was observed between patients with unruptured IA and those with ruptured IA (p = 0.418). Furthermore, VitD deficiency showed no association with aSAH in this study (p = 0.339).

To control for confounders, PSM was performed in a 1:1 ratio based on sex, age, BMI, diabetes, hypertension, hyperlipidemia, smoking, alcohol consumption, blood test date, and presence of multiple aneurysms. A total of 112 patients with ruptured IA were successfully matched to 112 patients with unruptured IA. Following PSM, no significant differences were observed in the distribution of the aforementioned variables. VitD levels and deficiency remained unassociated with aSAH (p > 0.05).

Additionally, RCS regression analysis showed no significant nonlinear association between serum VitD levels and the risk of IA rupture (p = 0.739), nor a significant overall association (p = 0.865), further supporting the findings before and after PSM (Figure 2).

FIGURE 2

Restricted cubic spline regression model depicting the association between serum vitamin D (VitD) levels and the odds of ruptured intracranial aneurysms.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Associations of Vitamin D With IA Rupture in the Observational Study Source: Associations of Vitamin D With IA Rupture in the Observational Study Source: Associations of Vitamin D With IA Rupture in the Observational Study Source: Associations of Vitamin D With IA Rupture in the Observational Study Source: Associations of Vitamin D With IA Rupture in the Observational Study Source: Associations of Vitamin D With IA Rupture in the Observational Study

The Causal Associations Between Vitamin D Status and IA Rupture in MR Analysis

Results: The Causal Associations Between Vitamin D Status and IA Rupture in MR Analysis

The IVW‐MR analysis revealed no causal relationship between VitD levels and the risks of aSAH (p = 0.966; OR, 1.00; 95% CI, 0.82 to 1.23) or unruptured IA (p = 0.74; OR, 0.95; 95% CI, 0.68 to 1.31) (Figure 3). These findings remained consistent across multiple MR methods, including weighted median, MR‐Egger, weighted mode, and simple mode approaches, and were replicated in an independent cohort (Table 2). Scatter plots and forest plots further confirmed these findings (Figures S1 and S2).

All SNPs used as instrumental variables (IVs) exhibited F‐statistics exceeding 20, indicating minimal weak instrument bias (Files S2: , S5). Sensitivity and heterogeneity analyses revealed no evidence of pleiotropy or heterogeneity (Table 3), supporting the robustness and reliability of the MR findings. Leave‐one‐out analysis further validated these results (Figure S3).

FIGURE 3

Forest plots for the causal associations of vitamin D (VitD) levels with ruptured intracranial aneurysms or unruptured intracranial aneurysms (UIAs) in discovery cohort.

Figure image at the original source: open the original paper. This file is not included in this text import.
TABLE 2

The MR results of the replication cohort.

ExposureMR methodSNP p OR (95% CI)
RIAVitamin DMR Egger930.9570.993 (0.777 to 1.270)
Weighted median930.4170.891 (0.675 to 1.177)
Inverse variance weighted930.3891.076 (0.911 to 1.270)
Simple mode930.7450.907 (0.504 to 1.633)
Weighted mode930.9481.007 (0.821 to 1.234)
UIAVitamin DMR Egger930.4100.874 (0.636 to 1.202)
Weighted median930.2310.803 (0.561 to 1.150)
Inverse variance weighted930.3711.103 (0.889 to 1.369)
Simple mode930.0052.910 (1.413 to 5.990)
Weighted mode930.5960.928 (0.706 to 1.221)

Abbreviations: RIA, Ruptured intracranial aneurysms; UIA, Unruptured intracranial aneurysms.

TABLE 3

Heterogeneity and pleiotropy tests of MR in discovery and replication cohort.

CohortTestOutcomeExposureMethodEffect size p
DiscoveryHeterogeneityRIAVitamin DCochran’s Q test66.0 (QMR Egger)0.169
66.1 (QIVW)0.192
UIAVitamin DCochran’s Q test69.8 (QMR Egger)0.101
70.2 (QIVW)0.112
PleiotropyRIAVitamin DMR‐Egger regression0.001 (Egger regression intercept)0.825
UIAVitamin DMR‐Egger regression−0.005 (Egger regression intercept)0.580
ReplicationHeterogeneityRIAVitamin DCochran’s Q test110.8 (Q MR Egger)0.078
111.7 (Q IVW)0.080
UIAVitamin DCochran’s Q test88.6 (Q MR Egger)0.551
92.4 (Q IVW)0.469
PleiotropyRIAVitamin DMR‐Egger regression0.003 (Egger regression intercept)0.393
UIAVitamin DMR‐Egger regression0.009 (Egger regression intercept)0.055

Abbreviations: RIA, ruptured intracranial aneurysms; UIA, unruptured intracranial aneurysms.

Source: The Causal Associations Between Vitamin D Status and IA Rupture in MR Analysis Source: The Causal Associations Between Vitamin D Status and IA Rupture in MR Analysis Source: The Causal Associations Between Vitamin D Status and IA Rupture in MR Analysis Source: The Causal Associations Between Vitamin D Status and IA Rupture in MR Analysis

Discussion

The relationship between VitD status and the risk of aSAH has received increasing attention due to accumulating evidence demonstrating the high prevalence of VitD deficiency in the population and the potential protective role of VitD in cardiovascular and cerebrovascular health [7, 8, 9, 16]. However, our study, which employed a large case: control design with PSM and two‐sample MR analysis, did not identify any association or causal relationship between VitD status and the risk of IA rupture.

VitD has a potential protective role in maintaining arterial health [17]. VitD receptors are present in vascular smooth muscle and endothelial cells. VitD deficiency is common in patients with IAs, even in those with aSAH and high sun exposure [18]. Although VitD might protect against IAs and reduce the risk of aSAH, our findings did not support this hypothesis, as VitD levels were not inversely associated with aSAH. A previous cross‐sectional study found higher VitD levels in patients with unruptured IAs than in those with ruptured IAs, with VitD independently associated with rupture risk [12].

However, that study had a small sample size and lacked PSM analysis. Our use of PSM balanced baseline characteristics between ruptured and unruptured IA groups, minimizing confounders such as age, sex, and comorbidities. Despite this, we found no significant difference in VitD levels between patients with ruptured or unruptured IA, and VitD deficiency was not associated with aSAH. Our results were consistent with a previous study [10], which found no difference in VitD levels between ruptured and unruptured IA patients, despite higher rates of hypovitaminosis D in IA patients requiring treatment compared to patients without IA.

However, our observational study may still be affected by uncontrolled confounders, such as lifestyle, dietary habits, sunlight exposure, and diseases or medications influencing VitD metabolism, which could potentially impact serum VitD levels and our findings. Future studies incorporating detailed lifestyle and environmental data are warranted to better account for these influences.

To address this limitation, we performed MR analysis, which utilizes genetic variants as instrumental variables to infer causal relationships. This analysis revealed no causal association between genetically determined VitD levels and IA rupture, consistent with prior MR studies utilizing distinct GWAS cohorts that also found no causal effect of VitD on IA rupture. We further used a restricted cubic spline regression model to evaluate potential nonlinear associations between serum VitD levels and IA rupture risk. The analysis revealed no significant linear or nonlinear relationship, thereby reinforcing our findings.

These results suggest that previously reported associations may be attributable to residual confounding or unmeasured biases. Although lower VitD levels were frequently observed in aneurysm patients, a recent meta‐analysis of VitD intervention trials failed to demonstrate a significant reduction in cardiovascular events with VitD supplementation, suggesting that lower VitD levels may represent an epiphenomenon rather than a causative factor [19]. One recent study reported VitD deficiency could promote IA rupture in a murine model [20]. However, all SAH murine models have inherent limitations, and the specific animal model used in that study may not fully replicate human aneurysm rupture mechanisms.

Therefore, these findings cannot be directly extrapolated to humans.

The biological mechanisms through which VitD influences vascular health may not directly relate to the pathophysiology of IA rupture. Although VitD may contribute to general vascular maintenance, the specific processes leading to aneurysm formation and rupture: such as hemodynamic stress, vascular wall degeneration, and inflammatory infiltration: may be less affected by VitD levels. Additionally, the VitD threshold for vascular protection may be lower than deficiency levels, meaning even “low” VitD levels could suffice for vascular integrity. However, studies indicate that VitD has anti‐inflammatory effects [21], and cerebrovascular inflammation is a major pathological factor for aneurysm rupture.

Low VitD levels are also associated with risk factors for aSAH, such as hypertension, hyperlipidemia, and hyperhomocysteinemia [22]. Therefore, our findings should be interpreted with caution. An alternative explanation is that the relationship between VitD and IA rupture is more complex than a linear association. VitD may directly or indirectly influence measurable and unmeasurable factors that contribute to the pathological progression of aneurysms. Its vascular effects might also be more pronounced in specific subgroups, such as individuals with certain comorbidities or genetic predispositions, and these effects may have been attenuated in our overall study population.

Although our study did not identify a significant association between VitD levels and IA rupture, this finding does not rule out VitD’s potential role in other aspects of aneurysm biology, such as formation or progression. Future studies should investigate these areas through longitudinal study designs or by focusing on subgroups more susceptible to the effects of VitD. Further research should also explore interactions between VitD and other factors, such as genetic variation, environmental exposures, or comorbidities, which may modulate IA rupture risk.

For instance, VitD might exert protective effects only in individuals with specific genetic profiles or under particular environmental conditions. Elucidating these interactions could provide deeper insights into VitD’s role in vascular pathophysiology.

The strengths of our study include the utilization of PSM and MR analysis to mitigate confounding and establish causal inferences. PSM effectively balances control groups and reduces selection bias in observational studies, while MR reliably evaluates causality by employing genetic variants as instrumental variables for VitD levels, thereby minimizing confounding and reverse causation. However, the MR analysis design differs from our observational analysis. While the observational study compared VitD levels in patients with ruptured and unruptured IA, the MR analysis assessed genetically predicted VitD levels in relation to unruptured IA and aSAH risk versus general population controls.

Nevertheless, these complementary methods provide both real‐world and genetically informed insights into the potential role of VitD in the pathophysiology of IA.

However, our study has several limitations. First, while PSM balanced observed baseline characteristics, unmeasured confounders may have introduced bias. Second, MR analysis assumes the genetic variants used as IVs are associated with VitD levels but not with other factors affecting rupture risk. Third, although we selected genetic variants strongly associated with VitD levels, they may have unexplained pleiotropic effects. Fourth, MR assumes a linear relationship between VitD levels and rupture, which may not hold if a threshold or nonlinear effect exists.

Additionally, other clinical factors, including age, diabetes, and multiple aneurysms, were significantly associated with aSAH in our observational study but were excluded from MR analysis due to limited genetic instruments and research focus. Moreover, our MR analysis utilized GWAS data from European populations, whereas our observational cohort was Chinese. Genetic differences in VitD metabolism, such as SLC24A5, CYP2R1, and GC variants between Europeans and Asians, may limit the generalizability of our MR findings [23, 24]. Dietary, lifestyle, and environmental factors, such as sunlight exposure and pollution, could also affect VitD‐related genotype expression.

Future studies using East Asian GWAS data are needed to validate these results in more genetically similar cohorts. Finally, not all relevant SNPs were included, which may have influenced the robustness of causal inference. A large‐scale prospective study with long‐term follow‐up is still needed to confirm our findings.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

3.1

Associations of Vitamin D With IA Rupture in the Observational Study

The baseline characteristics are presented in Table 1. A total of 499 patients with 619 IAs were included in this study, comprising 337 (67.5%) females and 162 (32.5%) males. The median age was 58.0 years [52.0, 64.0], and the median BMI was 24.8 kg/m2 [22.3, 27.3]. Among these patients, 184 (36.9%) had ruptured IAs, and 105 (21.0%) had multiple IAs.

TABLE 1

Baseline information of enrolled patients before or after propensity score matching (PSM).

CharacteristicBefore PSMAfter PSM
Overall (n = 499)Unruptured (n = 315)Ruptured (n = 184) p Overall (n = 224)Unruptured (n = 112)Ruptured (n = 112) p
Sex (Female)337 (67.5)215 (43.1)122 (24.4)0.654 a 157 (70.1)80 (35.7)77 (34.4)0.662 a
Age (year)0.026 a 0.774 a
≤ 50110 (22.0)58 (11.6)52 (10.4)43 (19.2)24 (10.7)19 (8.5)
51 to 60178 (35.7)110 (22.0)68 (13.6)85 (37.9)41 (18.3)44 (19.6)
61 to 70168 (33.7)118 (23.6)50 (10.0)78 (34.8)37 (16.5)41 (18.3)
> 7043 (8.6)29 (5.8)14 (2.8)18 (8.0)9 (7.3)10 (8.1)
BMI0.699 a 0.625 b
Underweight15 (3.0)9 (1.8)6 (1.2)7 (3.1)3 (1.3)4 (1.8)
Normal188 (37.9)114 (22.8)75 (15.0)89 (39.7)48 (21.4)41 (18.3)
Overweight204 (40.7)134 (26.9)69 (13.8)94 (42.0)47 (21.0)47 (21.0)
Obese92 (18.4)58 (11.6)34 (6.8)34 (15.2)14 (6.3)20 (8.9)
Smoking85 (17.0)50 (10.0)35 (7.0)0.367 a 36 (16.1)19 (8.5)17 (7.6)0.716 a
Drinking53 (10.6)29 (5.8)24 (4.8)0.180 a 25 (11.2)11 (4.9)14 (6.3)0.524 a
Diabetes70 (14.0)53 (10.6)17 (3.4)0.019 a 20 (8.9)9 (4.0)11 (4.9)0.639 a
Hypertension291 (58.3)184 (36.9)107 (21.4)0.955 a 132 (58.9)63 (28.1)69 (30.8)0.415 a
Hyperlipidemia142 (28.5)91 (18.2)51 (10.2)0.780 a 56 (25.0)28 (12.5)28 (12.5)1.000 a
Blood test dates0.147 a 0.885 a
Mar: May130 (26.1)81 (16.2)49 (9.8)60 (26.8)28 (12.5)32 (14.3)
Jun: Aug100 (20.0)57 (11.4)43 (8.6)45 (20.1)23 (10.3)22 (9.8)
Sep: Nov156 (31.3)96 (19.2)60 (12.0)73 (32.6)36 (16.1)37 (16.5)
Dec: Feb113 (22.6)81 (16.2)32 (6.4)46 (20.5)25 (11.2)21 (9.4)
Anterior circulating aneurysm477 (95.6)301 (60.3)176 (35.3)0.960 a 216 (96.4)110 (49.1)106 (47.3)0.280 a
Multiple aneurysms105 (21.0)56 (11.2)49 (9.8)0.019 a 45 (20.1)21 (9.4)24 (10.7)0.617 a
Vitamin D (ng/mL)17.0 [12.1 to 22.4]17.6 [12.6 to 22.6]16.3 [11.6 to 22.3]0.418 c 16.0 [11.5 to 21.3]15.8 [11.7 to 21.4]16.2 [10.8 to 21.2]0.904 c
Vitamin D levels0.339 a 0.947 a
Normal46 (9.2)26 (5.2)20 (4.0)22 (9.8)11 (4.9)11 (4.9)
Insufficient133 (26.7)90 (18.0)43 (8.6)48 (21.4)23 (10.3)25 (11.2)
Deficient320 (64.1)199 (39.9)121 (24.2)154 (68.8)78 (34.8)76 (33.9)

Note: Variables are presented as number of patients (%) or median (interquartile range), as appropriate.

a

p‐values calculated using Pearson’s chi‐square test.

b

p‐values calculated using Fisher’s exact test.

c

p‐values calculated using Mann: Whitney U test.

In this study, diabetes was inversely associated with the risk of aSAH (p = 0.034; odds ratio [OR], 0.53; 95% confidence interval [CI], 0.290 to 0.954), whereas multiple aneurysms increased the risk of aSAH (p = 0.006; OR, 1.88; 95% CI, 1.197 to 2.940) in multivariate analysis (Table S1). The prevalence of diabetes was 16.8% (53/315) in patients with unruptured IAs, compared with 9.2% (17/184) in patients with ruptured IAs. Conversely, multiple aneurysms were more prevalent in ruptured IA patients (26.6%, 49/184) than in unruptured IA patients (17.8%, 56/315).

Age, sex, BMI, smoking, alcohol use, hypertension, hyperlipidemia, and aneurysm location (anterior circulation) showed no significant association with aSAH in multivariate analysis (p > 0.05).

Blood test dates, as presented in Table 1, did not differ significantly between patients with unruptured IA and those with ruptured IA (p = 0.147). The median VitD level was 17.0 ng/mL [12.1 to 22.4]. VitD levels were normal in 9.2% of patients, insufficient in 26.7%, and deficient in 64.1% of patients. No significant difference in VitD levels was observed between patients with unruptured IA and those with ruptured IA (p = 0.418). Furthermore, VitD deficiency showed no association with aSAH in this study (p = 0.339).

To control for confounders, PSM was performed in a 1:1 ratio based on sex, age, BMI, diabetes, hypertension, hyperlipidemia, smoking, alcohol consumption, blood test date, and presence of multiple aneurysms. A total of 112 patients with ruptured IA were successfully matched to 112 patients with unruptured IA. Following PSM, no significant differences were observed in the distribution of the aforementioned variables. VitD levels and deficiency remained unassociated with aSAH (p > 0.05).

Additionally, RCS regression analysis showed no significant nonlinear association between serum VitD levels and the risk of IA rupture (p = 0.739), nor a significant overall association (p = 0.865), further supporting the findings before and after PSM (Figure 2).

FIGURE 2

Restricted cubic spline regression model depicting the association between serum vitamin D (VitD) levels and the odds of ruptured intracranial aneurysms.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.2

The Causal Associations Between Vitamin D Status and IA Rupture in MR Analysis

The IVW‐MR analysis revealed no causal relationship between VitD levels and the risks of aSAH (p = 0.966; OR, 1.00; 95% CI, 0.82 to 1.23) or unruptured IA (p = 0.74; OR, 0.95; 95% CI, 0.68 to 1.31) (Figure 3). These findings remained consistent across multiple MR methods, including weighted median, MR‐Egger, weighted mode, and simple mode approaches, and were replicated in an independent cohort (Table 2). Scatter plots and forest plots further confirmed these findings (Figures S1 and S2).

All SNPs used as instrumental variables (IVs) exhibited F‐statistics exceeding 20, indicating minimal weak instrument bias (Files S2: , S5). Sensitivity and heterogeneity analyses revealed no evidence of pleiotropy or heterogeneity (Table 3), supporting the robustness and reliability of the MR findings. Leave‐one‐out analysis further validated these results (Figure S3).

FIGURE 3

Forest plots for the causal associations of vitamin D (VitD) levels with ruptured intracranial aneurysms or unruptured intracranial aneurysms (UIAs) in discovery cohort.

Figure image at the original source: open the original paper. This file is not included in this text import.
TABLE 2

The MR results of the replication cohort.

ExposureMR methodSNP p OR (95% CI)
RIAVitamin DMR Egger930.9570.993 (0.777 to 1.270)
Weighted median930.4170.891 (0.675 to 1.177)
Inverse variance weighted930.3891.076 (0.911 to 1.270)
Simple mode930.7450.907 (0.504 to 1.633)
Weighted mode930.9481.007 (0.821 to 1.234)
UIAVitamin DMR Egger930.4100.874 (0.636 to 1.202)
Weighted median930.2310.803 (0.561 to 1.150)
Inverse variance weighted930.3711.103 (0.889 to 1.369)
Simple mode930.0052.910 (1.413 to 5.990)
Weighted mode930.5960.928 (0.706 to 1.221)

Abbreviations: RIA, Ruptured intracranial aneurysms; UIA, Unruptured intracranial aneurysms.

TABLE 3

Heterogeneity and pleiotropy tests of MR in discovery and replication cohort.

CohortTestOutcomeExposureMethodEffect size p
DiscoveryHeterogeneityRIAVitamin DCochran’s Q test66.0 (QMR Egger)0.169
66.1 (QIVW)0.192
UIAVitamin DCochran’s Q test69.8 (QMR Egger)0.101
70.2 (QIVW)0.112
PleiotropyRIAVitamin DMR‐Egger regression0.001 (Egger regression intercept)0.825
UIAVitamin DMR‐Egger regression−0.005 (Egger regression intercept)0.580
ReplicationHeterogeneityRIAVitamin DCochran’s Q test110.8 (Q MR Egger)0.078
111.7 (Q IVW)0.080
UIAVitamin DCochran’s Q test88.6 (Q MR Egger)0.551
92.4 (Q IVW)0.469
PleiotropyRIAVitamin DMR‐Egger regression0.003 (Egger regression intercept)0.393
UIAVitamin DMR‐Egger regression0.009 (Egger regression intercept)0.055

Abbreviations: RIA, ruptured intracranial aneurysms; UIA, unruptured intracranial aneurysms.

Source: Results Source: Results

Conclusion

Our study did not demonstrate an association or a causal relationship between VitD levels and aneurysmal subarachnoid hemorrhage (aSAH). The inverse associations observed in previous cohort studies may be attributable to confounding factors or reverse causation. Although VitD deficiency is common in patients with aSAH, supplementation may not prevent aneurysm rupture.

Source: Conclusion
Authors’ abstract

ABSTRACT

Background

Vitamin D (VitD) may protect arterial health, but its link to cerebral aneurysm rupture remains unclear. This study aims to investigate the correlation between serum VitD levels and the risk of aneurysmal subarachnoid hemorrhage (aSAH).

Methods

This retrospective study included patients with ruptured or unruptured aneurysms treated between 2018 and 2021. Univariate and multivariate analyses were conducted. Propensity score matching (PSM) analysis was conducted to balance confounding factors. Furthermore, the causal relationship between VitD and aSAH was investigated using a two‐sample Mendelian randomization (MR) analysis. Summary‐level data for the exposure (VitD) and outcome (aSAH) were obtained from public genome‐wide association study datasets. Multiple MR methods, including inverse variance weighted, MR‐Egger, weighted median, simple mode, and weighted mode, were utilized to assess causality.

Sensitivity analyses were conducted to evaluate the robustness and reliability of the causal estimates.

Results

A total of 499 patients with 619 intracranial aneurysms were included. Among them, 337 (68%) were female, 184 cases (36.9%) had ruptured aneurysms, and 105 (21.0%) had multiple aneurysms. VitD levels and VitD deficiency showed no association with aSAH in univariate or multivariate analysis before PSM (p > 0.05). After PSM (112 matched aSAH patients), VitD levels and VitD deficiency remained unassociated with the risk of aSAH (p = 0.947). MR analysis, including inverse variance weighted methods, found no causal link between VitD levels and aSAH (OR: 1.00; 95% CI: 0.82 to 1.23; p = 0.966).

Conclusion

This study found that serum VitD levels are neither associated with nor causally linked to aSAH. The inverse associations observed in previous studies may be attributed to confounding factors or reverse causation. A prospective, large‐scale study with long‐term follow‐up is warranted to validate these findings.

Read the full paper
1

Introduction

Intracranial aneurysms (IAs) are abnormal dilations of the cerebral arterial wall, posing a significant health risk due to their potential rupture, which can cause subarachnoid hemorrhage (SAH), a life‐threatening condition with high morbidity and mortality [1]. Incidental IAs are increasingly diagnosed owing to the widespread use of noninvasive neuroimaging. However, not all unruptured IAs rupture during a patient’s lifetime. Clinical factors such as hypertension, smoking, history of SAH, as well as aneurysm size and location, have been associated with IA growth and rupture [2, 3].

Tools such as the ELAPSS and PHASES scores, which incorporate these factors, have been developed to predict the risk of IA growth and rupture [4, 5]. Nevertheless, the literature lacks appropriate hematological indices for predicting aneurysm rupture.

While the pathological mechanisms underlying IA rupture remain incompletely understood, factors such as inflammation, oxidative stress, hemodynamic stress, and genetic predispositions are considered contributing factors [2, 3]. Abnormal blood flow and shear stress may compromise vascular integrity, while inflammation and oxidative stress could further damage the aneurysm wall, thereby increasing the rupture risk [2, 3, 6]. Vitamin D (VitD), a fat‐soluble steroid vitamin essential for calcium homeostasis and immune regulation, may confer vascular health benefits due to its anti‐inflammatory and antioxidative properties [7, 8].

Low levels of VitD are associated with elevated vascular inflammation, oxidative stress, endothelial dysfunction, and increased risk of cardiovascular and cerebrovascular events, including hypertension, atherosclerosis, myocardial infarction, and stroke [7, 8, 9]. VitD deficiency is also prevalent among IA patients [10, 11]. However, its relationship with IA rupture remains unclear. One study reported an inverse correlation between VitD levels and the risk of aneurysmal subarachnoid hemorrhage (aSAH) [12], whereas another found no association [11].

These discrepancies may arise from variations in sample size, study populations, methodologies, or unaccounted confounders. Additionally, VitD deficiency could result from aneurysm rupture, suggesting potential reverse causality. Thus, the specific role of VitD in aSAH remains controversial, and further research is required to determine whether VitD deficiency is associated with IA rupture.

Therefore, in this study, a large case: control study with propensity score matching (PSM) to balance confounding factors was conducted to investigate the potential association between VitD levels and aSAH. However, observational studies remain vulnerable to unmeasured confounders. To address this limitation, we also performed a two‐sample Mendelian randomization (MR) analysis to explore potential causal relationships. By integrating these methods, this study aims to provide high‐quality evidence regarding the relationship between VitD status and aSAH. The findings may improve our understanding of IA rupture mechanisms.

2

Materials and Methods

2.1

Observational Study Design

This retrospective case: control study comprised consecutive patients with IA treated at Qilu Hospital of Shandong University between March 2018 and May 2021. The study was approved by the Ethics Committee of Qilu Hospital of Shandong University, and written informed consent was obtained from all participants prior to enrollment. All IAs were confirmed using computed tomography (CT), magnetic resonance imaging (MRI), or digital subtraction angiography (DSA). SAH was confirmed via CT scans. Ruptured IAs were defined as cases presenting with aneurysmal SAH, regardless of the number of aneurysms present, while unruptured IAs were defined as patients with at least one aneurysm and no history of SAH.

Exclusion criteria were as follows: (1) recent administration of VitD supplements or glucocorticoids within 1 month prior to the study; (2) concomitant vascular diseases, such as arteriovenous malformations, moyamoya disease, or arteriovenous fistulas; (3) recurrent, fusiform, traumatic, bacterial, or dissecting aneurysms; (4) aneurysmal SAH occurring more than 72 h before admission; (5) SAH of unknown etiology or non‐aneurysmal SAH; and (6) age < 18 years. Ultimately, 499 patients with either unruptured or ruptured IAs were included in the study. The study flowchart is presented in Figure 1A.

FIGURE 1

The flow chart of the present study.

Figure image at the original source: open the original paper. This file is not included in this text import.

The patients’ demographic characteristics, comorbidities (including diabetes mellitus, hypertension, and hyperlipidemia), and aneurysm characteristics (such as location and number) were recorded. For patients with multiple aneurysms, the study evaluated the location (anterior or posterior circulation) of the primary aneurysm treated during hospitalization. Fasting venous blood samples were collected within 24 h of admission to measure 25‐hydroxyvitamin D levels and conduct lipid profile tests, including triglycerides (TG), total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), and high‐density lipoprotein cholesterol (HDL‐C). Body mass index (BMI) was categorized as underweight (≤ 18.5 kg/m2), normal weight (18.5 to 24 kg/m2), overweight (24 to 28 kg/m2), or obese (> 28 kg/m2).

Hypertension was defined as a documented history of the condition (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg), irrespective of antihypertensive treatment. Diabetes mellitus was defined as patients receiving antidiabetic medication, a fasting glucose level ≥ 7 mmol/L from previous health assessments, or a hemoglobin A1c level ≥ 6.5%. Hyperlipidemia was defined as lipid‐lowering medication use or fasting plasma TC ≥ 6 mmol/L, TG ≥ 2 mmol/L, or LDL ≥ 3.5 mmol/L. Current smoking was defined as consumption of ≥ 5 cigarettes per day, and alcohol consumption as intake of ≥ 150 g per week.

VitD levels were categorized as deficient (< 20 ng/mL), insufficient (20 to 29 ng/mL), or normal (≥ 30 ng/mL).

Statistical analyses were performed using SPSS 25.0 (IBM Corp.). Continuous variables were expressed as mean ± standard deviation or median [interquartile range], depending on their distribution. The Shapiro: Wilk test was used to assess normality, with a p‐value < 0.05 indicating a deviation from normal distribution. Group comparisons were conducted using Student’s t‐test for normally distributed variables and the Mann: Whitney U test for non‐normally distributed variables. Categorical variables were expressed as frequencies and percentages and were compared using the χ 2 test or Fisher’s exact test.

Factors with p < 0.1 in univariate analysis were included in binary logistic regression analysis using an enter process to identify independent predictors. PSM was used to balance confounding factors between patients with and without aneurysmal SAH. A one‐to‐one PSM analysis using the nearest neighbor method with a caliper value of 0.01 was conducted to adjust for imbalanced factors. A restricted cubic spline (RCS) regression model was employed to examine potential linear or nonlinear associations between serum VitD levels and the risk of aSAH.

Four knots were positioned at the 5th, 35th, 65th, and 95th percentiles of the VitD distribution, with the median serving as the reference point. The RCS model was fitted using the “rms” package (version 6.8 to 2), and spline plots were generated using the “plotRCS” package (version 0.1.5) in R software (version 4.4.1). Statistical significance was defined as a two‐tailed p‐value < 0.05.

2.2

MR Analysis

A two‐sample MR analysis was performed to investigate the causal relationship between VitD levels and aSAH. Figure 1B shows the analysis flowchart.

Genetic instruments for VitD levels were obtained from genome‐wide association studies (GWAS) datasets available through the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/), a public resource for investigating genetic associations with complex traits. Summary‐level GWAS data on IAs were derived from two large cohorts: the discovery cohort, conducted by the International Stroke Genetics Consortium (ISGC) with individuals of European ancestry, and the replication cohort from FinnGen. The discovery cohort included 5140 ruptured cases, 2070 unruptured cases, and 71,934 controls, while the replication cohort had 6236 ruptured cases, 3014 unruptured cases, and 412,105 controls.

Additional details regarding the data sources used in this study are provided in File S1.

From these GWAS datasets, single nucleotide polymorphisms (SNPs) significantly associated with VitD levels (p < 5 × 10−8) were selected as candidate instrumental variables (IVs). Linkage disequilibrium (LD) analysis was conducted to ensure SNP independence, applying a threshold of LD‐r 2 < 0.001 and a clumping distance threshold of > 10,000 kb. The F‐statistic [F = R 2(N‐2)/(1‐R 2)] was calculated to evaluate IV strength, with SNPs failing to meet the criterion of F ≥ 10 excluded to mitigate weak instrument bias, thereby maintaining the robustness of the analysis.

The inverse variance‐weighted (IVW) method was employed as the primary approach for causal estimation, providing reliable results in the absence of heterogeneity or horizontal pleiotropy. Supplementary methods: including MR‐Egger regression, weighted median, simple mode, and weighted mode: were used to ensure robustness under varying conditions. Heterogeneity was assessed using Cochran’s Q test, and if heterogeneity was detected (p < 0.05), adjusted results were reanalyzed [13]. Horizontal pleiotropy was evaluated using the MR‐Egger intercept method, with p > 0.05 indicating no pleiotropy and supporting MR reliability [14].

The leave‐one‐out (LOO) method was applied to systematically exclude each SNP to assess result stability. All analyses were conducted using R software (version 4.4.1) with the “TwoSampleMR” package [15], with statistical significance defined as p < 0.05.

3

Results

3.1

Associations of Vitamin D With IA Rupture in the Observational Study

The baseline characteristics are presented in Table 1. A total of 499 patients with 619 IAs were included in this study, comprising 337 (67.5%) females and 162 (32.5%) males. The median age was 58.0 years [52.0, 64.0], and the median BMI was 24.8 kg/m2 [22.3, 27.3]. Among these patients, 184 (36.9%) had ruptured IAs, and 105 (21.0%) had multiple IAs.

TABLE 1

Baseline information of enrolled patients before or after propensity score matching (PSM).

CharacteristicBefore PSMAfter PSM
Overall (n = 499)Unruptured (n = 315)Ruptured (n = 184) p Overall (n = 224)Unruptured (n = 112)Ruptured (n = 112) p
Sex (Female)337 (67.5)215 (43.1)122 (24.4)0.654 a 157 (70.1)80 (35.7)77 (34.4)0.662 a
Age (year)0.026 a 0.774 a
≤ 50110 (22.0)58 (11.6)52 (10.4)43 (19.2)24 (10.7)19 (8.5)
51 to 60178 (35.7)110 (22.0)68 (13.6)85 (37.9)41 (18.3)44 (19.6)
61 to 70168 (33.7)118 (23.6)50 (10.0)78 (34.8)37 (16.5)41 (18.3)
> 7043 (8.6)29 (5.8)14 (2.8)18 (8.0)9 (7.3)10 (8.1)
BMI0.699 a 0.625 b
Underweight15 (3.0)9 (1.8)6 (1.2)7 (3.1)3 (1.3)4 (1.8)
Normal188 (37.9)114 (22.8)75 (15.0)89 (39.7)48 (21.4)41 (18.3)
Overweight204 (40.7)134 (26.9)69 (13.8)94 (42.0)47 (21.0)47 (21.0)
Obese92 (18.4)58 (11.6)34 (6.8)34 (15.2)14 (6.3)20 (8.9)
Smoking85 (17.0)50 (10.0)35 (7.0)0.367 a 36 (16.1)19 (8.5)17 (7.6)0.716 a
Drinking53 (10.6)29 (5.8)24 (4.8)0.180 a 25 (11.2)11 (4.9)14 (6.3)0.524 a
Diabetes70 (14.0)53 (10.6)17 (3.4)0.019 a 20 (8.9)9 (4.0)11 (4.9)0.639 a
Hypertension291 (58.3)184 (36.9)107 (21.4)0.955 a 132 (58.9)63 (28.1)69 (30.8)0.415 a
Hyperlipidemia142 (28.5)91 (18.2)51 (10.2)0.780 a 56 (25.0)28 (12.5)28 (12.5)1.000 a
Blood test dates0.147 a 0.885 a
Mar: May130 (26.1)81 (16.2)49 (9.8)60 (26.8)28 (12.5)32 (14.3)
Jun: Aug100 (20.0)57 (11.4)43 (8.6)45 (20.1)23 (10.3)22 (9.8)
Sep: Nov156 (31.3)96 (19.2)60 (12.0)73 (32.6)36 (16.1)37 (16.5)
Dec: Feb113 (22.6)81 (16.2)32 (6.4)46 (20.5)25 (11.2)21 (9.4)
Anterior circulating aneurysm477 (95.6)301 (60.3)176 (35.3)0.960 a 216 (96.4)110 (49.1)106 (47.3)0.280 a
Multiple aneurysms105 (21.0)56 (11.2)49 (9.8)0.019 a 45 (20.1)21 (9.4)24 (10.7)0.617 a
Vitamin D (ng/mL)17.0 [12.1 to 22.4]17.6 [12.6 to 22.6]16.3 [11.6 to 22.3]0.418 c 16.0 [11.5 to 21.3]15.8 [11.7 to 21.4]16.2 [10.8 to 21.2]0.904 c
Vitamin D levels0.339 a 0.947 a
Normal46 (9.2)26 (5.2)20 (4.0)22 (9.8)11 (4.9)11 (4.9)
Insufficient133 (26.7)90 (18.0)43 (8.6)48 (21.4)23 (10.3)25 (11.2)
Deficient320 (64.1)199 (39.9)121 (24.2)154 (68.8)78 (34.8)76 (33.9)

Note: Variables are presented as number of patients (%) or median (interquartile range), as appropriate.

a

p‐values calculated using Pearson’s chi‐square test.

b

p‐values calculated using Fisher’s exact test.

c

p‐values calculated using Mann: Whitney U test.

In this study, diabetes was inversely associated with the risk of aSAH (p = 0.034; odds ratio [OR], 0.53; 95% confidence interval [CI], 0.290 to 0.954), whereas multiple aneurysms increased the risk of aSAH (p = 0.006; OR, 1.88; 95% CI, 1.197 to 2.940) in multivariate analysis (Table S1). The prevalence of diabetes was 16.8% (53/315) in patients with unruptured IAs, compared with 9.2% (17/184) in patients with ruptured IAs. Conversely, multiple aneurysms were more prevalent in ruptured IA patients (26.6%, 49/184) than in unruptured IA patients (17.8%, 56/315).

Age, sex, BMI, smoking, alcohol use, hypertension, hyperlipidemia, and aneurysm location (anterior circulation) showed no significant association with aSAH in multivariate analysis (p > 0.05).

Blood test dates, as presented in Table 1, did not differ significantly between patients with unruptured IA and those with ruptured IA (p = 0.147). The median VitD level was 17.0 ng/mL [12.1 to 22.4]. VitD levels were normal in 9.2% of patients, insufficient in 26.7%, and deficient in 64.1% of patients. No significant difference in VitD levels was observed between patients with unruptured IA and those with ruptured IA (p = 0.418). Furthermore, VitD deficiency showed no association with aSAH in this study (p = 0.339).

To control for confounders, PSM was performed in a 1:1 ratio based on sex, age, BMI, diabetes, hypertension, hyperlipidemia, smoking, alcohol consumption, blood test date, and presence of multiple aneurysms. A total of 112 patients with ruptured IA were successfully matched to 112 patients with unruptured IA. Following PSM, no significant differences were observed in the distribution of the aforementioned variables. VitD levels and deficiency remained unassociated with aSAH (p > 0.05).

Additionally, RCS regression analysis showed no significant nonlinear association between serum VitD levels and the risk of IA rupture (p = 0.739), nor a significant overall association (p = 0.865), further supporting the findings before and after PSM (Figure 2).

FIGURE 2

Restricted cubic spline regression model depicting the association between serum vitamin D (VitD) levels and the odds of ruptured intracranial aneurysms.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.2

The Causal Associations Between Vitamin D Status and IA Rupture in MR Analysis

The IVW‐MR analysis revealed no causal relationship between VitD levels and the risks of aSAH (p = 0.966; OR, 1.00; 95% CI, 0.82 to 1.23) or unruptured IA (p = 0.74; OR, 0.95; 95% CI, 0.68 to 1.31) (Figure 3). These findings remained consistent across multiple MR methods, including weighted median, MR‐Egger, weighted mode, and simple mode approaches, and were replicated in an independent cohort (Table 2). Scatter plots and forest plots further confirmed these findings (Figures S1 and S2).

All SNPs used as instrumental variables (IVs) exhibited F‐statistics exceeding 20, indicating minimal weak instrument bias (Files S2: , S5). Sensitivity and heterogeneity analyses revealed no evidence of pleiotropy or heterogeneity (Table 3), supporting the robustness and reliability of the MR findings. Leave‐one‐out analysis further validated these results (Figure S3).

FIGURE 3

Forest plots for the causal associations of vitamin D (VitD) levels with ruptured intracranial aneurysms or unruptured intracranial aneurysms (UIAs) in discovery cohort.

Figure image at the original source: open the original paper. This file is not included in this text import.
TABLE 2

The MR results of the replication cohort.

ExposureMR methodSNP p OR (95% CI)
RIAVitamin DMR Egger930.9570.993 (0.777 to 1.270)
Weighted median930.4170.891 (0.675 to 1.177)
Inverse variance weighted930.3891.076 (0.911 to 1.270)
Simple mode930.7450.907 (0.504 to 1.633)
Weighted mode930.9481.007 (0.821 to 1.234)
UIAVitamin DMR Egger930.4100.874 (0.636 to 1.202)
Weighted median930.2310.803 (0.561 to 1.150)
Inverse variance weighted930.3711.103 (0.889 to 1.369)
Simple mode930.0052.910 (1.413 to 5.990)
Weighted mode930.5960.928 (0.706 to 1.221)

Abbreviations: RIA, Ruptured intracranial aneurysms; UIA, Unruptured intracranial aneurysms.

TABLE 3

Heterogeneity and pleiotropy tests of MR in discovery and replication cohort.

CohortTestOutcomeExposureMethodEffect size p
DiscoveryHeterogeneityRIAVitamin DCochran’s Q test66.0 (QMR Egger)0.169
66.1 (QIVW)0.192
UIAVitamin DCochran’s Q test69.8 (QMR Egger)0.101
70.2 (QIVW)0.112
PleiotropyRIAVitamin DMR‐Egger regression0.001 (Egger regression intercept)0.825
UIAVitamin DMR‐Egger regression−0.005 (Egger regression intercept)0.580
ReplicationHeterogeneityRIAVitamin DCochran’s Q test110.8 (Q MR Egger)0.078
111.7 (Q IVW)0.080
UIAVitamin DCochran’s Q test88.6 (Q MR Egger)0.551
92.4 (Q IVW)0.469
PleiotropyRIAVitamin DMR‐Egger regression0.003 (Egger regression intercept)0.393
UIAVitamin DMR‐Egger regression0.009 (Egger regression intercept)0.055

Abbreviations: RIA, ruptured intracranial aneurysms; UIA, unruptured intracranial aneurysms.

4

Discussion

The relationship between VitD status and the risk of aSAH has received increasing attention due to accumulating evidence demonstrating the high prevalence of VitD deficiency in the population and the potential protective role of VitD in cardiovascular and cerebrovascular health [7, 8, 9, 16]. However, our study, which employed a large case: control design with PSM and two‐sample MR analysis, did not identify any association or causal relationship between VitD status and the risk of IA rupture.

VitD has a potential protective role in maintaining arterial health [17]. VitD receptors are present in vascular smooth muscle and endothelial cells. VitD deficiency is common in patients with IAs, even in those with aSAH and high sun exposure [18]. Although VitD might protect against IAs and reduce the risk of aSAH, our findings did not support this hypothesis, as VitD levels were not inversely associated with aSAH. A previous cross‐sectional study found higher VitD levels in patients with unruptured IAs than in those with ruptured IAs, with VitD independently associated with rupture risk [12].

However, that study had a small sample size and lacked PSM analysis. Our use of PSM balanced baseline characteristics between ruptured and unruptured IA groups, minimizing confounders such as age, sex, and comorbidities. Despite this, we found no significant difference in VitD levels between patients with ruptured or unruptured IA, and VitD deficiency was not associated with aSAH. Our results were consistent with a previous study [10], which found no difference in VitD levels between ruptured and unruptured IA patients, despite higher rates of hypovitaminosis D in IA patients requiring treatment compared to patients without IA.

However, our observational study may still be affected by uncontrolled confounders, such as lifestyle, dietary habits, sunlight exposure, and diseases or medications influencing VitD metabolism, which could potentially impact serum VitD levels and our findings. Future studies incorporating detailed lifestyle and environmental data are warranted to better account for these influences.

To address this limitation, we performed MR analysis, which utilizes genetic variants as instrumental variables to infer causal relationships. This analysis revealed no causal association between genetically determined VitD levels and IA rupture, consistent with prior MR studies utilizing distinct GWAS cohorts that also found no causal effect of VitD on IA rupture. We further used a restricted cubic spline regression model to evaluate potential nonlinear associations between serum VitD levels and IA rupture risk. The analysis revealed no significant linear or nonlinear relationship, thereby reinforcing our findings.

These results suggest that previously reported associations may be attributable to residual confounding or unmeasured biases. Although lower VitD levels were frequently observed in aneurysm patients, a recent meta‐analysis of VitD intervention trials failed to demonstrate a significant reduction in cardiovascular events with VitD supplementation, suggesting that lower VitD levels may represent an epiphenomenon rather than a causative factor [19]. One recent study reported VitD deficiency could promote IA rupture in a murine model [20]. However, all SAH murine models have inherent limitations, and the specific animal model used in that study may not fully replicate human aneurysm rupture mechanisms.

Therefore, these findings cannot be directly extrapolated to humans.

The biological mechanisms through which VitD influences vascular health may not directly relate to the pathophysiology of IA rupture. Although VitD may contribute to general vascular maintenance, the specific processes leading to aneurysm formation and rupture: such as hemodynamic stress, vascular wall degeneration, and inflammatory infiltration: may be less affected by VitD levels. Additionally, the VitD threshold for vascular protection may be lower than deficiency levels, meaning even “low” VitD levels could suffice for vascular integrity. However, studies indicate that VitD has anti‐inflammatory effects [21], and cerebrovascular inflammation is a major pathological factor for aneurysm rupture.

Low VitD levels are also associated with risk factors for aSAH, such as hypertension, hyperlipidemia, and hyperhomocysteinemia [22]. Therefore, our findings should be interpreted with caution. An alternative explanation is that the relationship between VitD and IA rupture is more complex than a linear association. VitD may directly or indirectly influence measurable and unmeasurable factors that contribute to the pathological progression of aneurysms. Its vascular effects might also be more pronounced in specific subgroups, such as individuals with certain comorbidities or genetic predispositions, and these effects may have been attenuated in our overall study population.

Although our study did not identify a significant association between VitD levels and IA rupture, this finding does not rule out VitD’s potential role in other aspects of aneurysm biology, such as formation or progression. Future studies should investigate these areas through longitudinal study designs or by focusing on subgroups more susceptible to the effects of VitD. Further research should also explore interactions between VitD and other factors, such as genetic variation, environmental exposures, or comorbidities, which may modulate IA rupture risk.

For instance, VitD might exert protective effects only in individuals with specific genetic profiles or under particular environmental conditions. Elucidating these interactions could provide deeper insights into VitD’s role in vascular pathophysiology.

The strengths of our study include the utilization of PSM and MR analysis to mitigate confounding and establish causal inferences. PSM effectively balances control groups and reduces selection bias in observational studies, while MR reliably evaluates causality by employing genetic variants as instrumental variables for VitD levels, thereby minimizing confounding and reverse causation. However, the MR analysis design differs from our observational analysis. While the observational study compared VitD levels in patients with ruptured and unruptured IA, the MR analysis assessed genetically predicted VitD levels in relation to unruptured IA and aSAH risk versus general population controls.

Nevertheless, these complementary methods provide both real‐world and genetically informed insights into the potential role of VitD in the pathophysiology of IA.

However, our study has several limitations. First, while PSM balanced observed baseline characteristics, unmeasured confounders may have introduced bias. Second, MR analysis assumes the genetic variants used as IVs are associated with VitD levels but not with other factors affecting rupture risk. Third, although we selected genetic variants strongly associated with VitD levels, they may have unexplained pleiotropic effects. Fourth, MR assumes a linear relationship between VitD levels and rupture, which may not hold if a threshold or nonlinear effect exists.

Additionally, other clinical factors, including age, diabetes, and multiple aneurysms, were significantly associated with aSAH in our observational study but were excluded from MR analysis due to limited genetic instruments and research focus. Moreover, our MR analysis utilized GWAS data from European populations, whereas our observational cohort was Chinese. Genetic differences in VitD metabolism, such as SLC24A5, CYP2R1, and GC variants between Europeans and Asians, may limit the generalizability of our MR findings [23, 24]. Dietary, lifestyle, and environmental factors, such as sunlight exposure and pollution, could also affect VitD‐related genotype expression.

Future studies using East Asian GWAS data are needed to validate these results in more genetically similar cohorts. Finally, not all relevant SNPs were included, which may have influenced the robustness of causal inference. A large‐scale prospective study with long‐term follow‐up is still needed to confirm our findings.

5

Conclusion

Our study did not demonstrate an association or a causal relationship between VitD levels and aneurysmal subarachnoid hemorrhage (aSAH). The inverse associations observed in previous cohort studies may be attributable to confounding factors or reverse causation. Although VitD deficiency is common in patients with aSAH, supplementation may not prevent aneurysm rupture.

Ethics Statement

The study was approved by the ethics committee of Qilu Hospital of Shandong University, and written informed consent was obtained from all the patients before enrollment.

Conflicts of Interest

The authors declare no conflicts of interest.

Supporting information

Figure S1: Scatter plots of the relationship between vitamin D levels and ruptured or unruptured intracranial aneurysms. Scatter plots illustrate the associations between vitamin D levels and ruptured or unruptured intracranial aneurysms in the discovery cohort (A and C) and the replication cohort (B and D). MR, Mendelian randomization; SNP, single nucleotide polymorphism.

Figure S2: Causal effects of individual SNPs in MR analyses. Forest plots show the estimated MR effect sizes of individual SNPs on ruptured or unruptured intracranial aneurysms by vitamin D levels in the discovery cohort (A and C) and the replication cohort (B and D). MR, Mendelian randomization; SNP, single nucleotide polymorphism.

Figure S3: Leave‐one‐out sensitivity analysis of MR results. Leave‐one‐out sensitivity analyses are shown for the discovery cohort (A and C) and the replication cohort (B and D). MR, Mendelian randomization.

Supplement file at the original source: open the original paper. This file is not included in this text import.

File S1: cns70617‐sup‐0002‐FileS1.xlsx.

Supplement file at the original source: open the original paper. This file is not included in this text import.

File S2: cns70617‐sup‐0003‐FileS2.xlsx.

Supplement file at the original source: open the original paper. This file is not included in this text import.

File S3: cns70617‐sup‐0004‐FileS3.xlsx.

Supplement file at the original source: open the original paper. This file is not included in this text import.

File S4: cns70617‐sup‐0005‐FileS4.xlsx.

Supplement file at the original source: open the original paper. This file is not included in this text import.

File S5: cns70617‐sup‐0006‐FileS5.xlsx.

Supplement file at the original source: open the original paper. This file is not included in this text import.

Table S1: Binary logistic regression between patients with ruptured intracranial aneurysms and patients with unruptured intracranial aneurysms.

Supplement file at the original source: open the original paper. This file is not included in this text import.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

References

1 M. H. Vlak , A. Algra , R. Brandenburg , and G. J. Rinkel , “Prevalence of Unruptured Intracranial Aneurysms, With Emphasis on Sex, Age, Comorbidity, Country, and Time Period: A Systematic Review and Meta‐Analysis ,” Lancet Neurology 10 , no. 7 (2011 ): 626Not reported636 . 21641282 10.1016/S1474-4422(11)70109-0
2 P. Texakalidis , A. Sweid , N. Mouchtouris , et al., “Aneurysm Formation, Growth, and Rupture: The Biology and Physics of Cerebral Aneurysms ,” World Neurosurgery 130 (2019 ): 277Not reported284 . 31323409 10.1016/j.wneu.2019.07.093
3 N. Chalouhi , B. L. Hoh , and D. Hasan , “Review of Cerebral Aneurysm Formation, Growth, and Rupture ,” Stroke 44 , no. 12 (2013 ): 3613Not reported3622 . 24130141 10.1161/STROKEAHA.113.002390
4 J. P. Greving , M. J. Wermer , R. D. Brown , Jr. , et al., “Development of the PHASES Score for Prediction of Risk of Rupture of Intracranial Aneurysms: A Pooled Analysis of Six Prospective Cohort Studies ,” Lancet Neurology 13 , no. 1 (2014 ): 59Not reported66 . 24290159 10.1016/S1474-4422(13)70263-1
5 D. Backes , G. J. E. Rinkel , J. P. Greving , et al., “ELAPSS Score for Prediction of Risk of Growth of Unruptured Intracranial Aneurysms ,” Neurology 88 , no. 17 (2017 ): 1600Not reported1606 . 28363976 10.1212/WNL.0000000000003865
6 R. Tulamo , J. Frösen , J. Hernesniemi , and M. Niemelä , “Inflammatory Changes in the Aneurysm Wall: A Review ,” Journal of Neurointerventional Surgery 10 , no. Suppl 1 (2018 ): i58Not reportedi67 . 30037960 10.1136/jnis.2009.002055.rep
7 G. Della Nera , L. Sabatino , M. Gaggini , F. Gorini , and C. Vassalle , “Vitamin D Determinants, Status, and Antioxidant/Anti‐Inflammatory‐Related Effects in Cardiovascular Risk and Disease: Not the Last Word in the Controversy ,” Antioxidants (Basel) 12 , no. 4 (2023 ): 948 . 37107323 10.3390/antiox12040948 PMC10135791
8 M. Nardin , M. Verdoia , S. Nardin , et al., “Vitamin D and Cardiovascular Diseases: From Physiology to Pathophysiology and Outcomes ,” Biomedicine 12 , no. 4 (2024 ): 768 . 10.3390/biomedicines12040768 PMC11048686 38672124
9 R. Zhou , M. Wang , H. Huang , W. Li , Y. Hu , and T. Wu , “Lower Vitamin D Status Is Associated With an Increased Risk of Ischemic Stroke: A Systematic Review and Meta‐Analysis ,” Nutrients 10 , no. 3 (2018 ): 277 . 29495586 10.3390/nu10030277 PMC5872695
10 J. Guan , M. Karsy , I. Eli , et al., “Increased Incidence of Hypovitaminosis D Among Patients Requiring Treatment for Cerebral Aneurysms ,” World Neurosurgery 88 (2016 ): 15Not reported20 . 26748168 10.1016/j.wneu.2015.12.075
11 A. Sharma and J. K. Sharma , “Association of Bone Mineral Density, Vitamin D, and Serum Calcium in Intracranial Aneurysm ,” Asian Journal of Neurosurgery 15 , no. 3 (2020 ): 521Not reported526 . 33145201 10.4103/ajns.AJNS_111_20 PMC7591171
12 S. Wei , X. Yuan , D. Li , et al., “Vitamin D Level Is Associated With Rupture of Intracranial Aneurysm in Patients With Subarachnoid Hemorrhage ,” Frontiers in Neurology 13 (2022 ): 890950. 36034296 10.3389/fneur.2022.890950 PMC9403761
13 J. P. Higgins , S. G. Thompson , J. J. Deeks , and D. G. Altman , “Measuring Inconsistency in Meta‐Analyses ,” BMJ 327 , no. 7414 (2003 ): 557Not reported560 . 12958120 10.1136/bmj.327.7414.557 PMC192859
14 S. Burgess and S. G. Thompson , “Interpreting Findings From Mendelian Randomization Using the MR‐Egger Method ,” European Journal of Epidemiology 32 , no. 5 (2017 ): 377Not reported389 . 28527048 10.1007/s10654-017-0255-x PMC5506233
15 G. Hemani , J. Zheng , B. Elsworth , et al., “The MR‐Base Platform Supports Systematic Causal Inference Across the Human Phenome ,” eLife 7 (2018 ): e34408 . 29846171 10.7554/eLife.34408 PMC5976434
16 W. B. Grant and B. J. Boucher , “How Follow‐Up Period in Prospective Cohort Studies Affects Relationship Between Baseline Serum 25(OH)D Concentration and Risk of Stroke and Major Cardiovascular Events ,” Nutrients 16 , no. 21 (2024 ): 3759. 39519592 10.3390/nu16213759 PMC11547645
17 S. M. Krishna , “Vitamin D as A Protector of Arterial Health: Potential Role in Peripheral Arterial Disease Formation ,” International Journal of Molecular Sciences 20 , no. 19 (2019 ): 4907. 31623356 10.3390/ijms20194907 PMC6801787
18 L. P. de Macêdo , T. R. de Castro , M. Torres Braga , et al., “The Relationship Between the Level of Vitamin D and Ruptured Intracranial Aneurysms Among Patients With High Sun Exposure ,” Scientific Reports 14 , no. 1 (2024 ): 3555 . 38347057 10.1038/s41598-024-53676-y PMC10861505
19 M. Barbarawi , B. Kheiri , Y. Zayed , et al., “Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta‐Analysis ,” JAMA Cardiology 4 , no. 8 (2019 ): 765Not reported776 . 31215980 10.1001/jamacardio.2019.1870 PMC6584896
20 T. Kimura , R. Rahmani , T. Miyamoto , et al., “Vitamin D Deficiency Promotes Intracranial Aneurysm Rupture ,” Journal of Cerebral Blood Flow and Metabolism 44 , no. 7 (2024 ): 1174Not reported1183 . 38241458 10.1177/0271678X241226750 PMC11179614
21 M. Izzo , A. Carrizzo , C. Izzo , et al., “Vitamin D: Not Just Bone Metabolism but a Key Player in Cardiovascular Diseases ,” Life (Basel) 11 , no. 5 (2021 ): 452 . 34070202 10.3390/life11050452 PMC8158519
22 C. J. Glueck , V. Jetty , M. Rothschild , et al., “Associations Between Serum 25‐Hydroxyvitamin D and Lipids, Lipoprotein Cholesterols, and Homocysteine ,” North American Journal of Medical Sciences 8 , no. 7 (2016 ): 284Not reported290 . 27583236 10.4103/1947-2714.187137 PMC4982357
23 P. Lips , “Vitamin D Status and Nutrition in Europe and Asia ,” Journal of Steroid Biochemistry and Molecular Biology 103 , no. 3 to 5 (2007 ): 620Not reported625 . 17287117 10.1016/j.jsbmb.2006.12.076
24 L. Duan , Z. Xue , H. Ji , D. Zhang , and Y. Wang , “Effects of CYP2R1 Gene Variants on Vitamin D Levels and Status: A Systematic Review and Meta‐Analysis ,” Gene 678 (2018 ): 361Not reported369 . 30120973 10.1016/j.gene.2018.08.056
Publication and source details

Original title: Serum Vitamin D Levels Were Not Associated With the Risk of Aneurysmal Subarachnoid Hemorrhage: A Large Cohort Study With Propensity Score Matching and Mendelian Randomization Analysis

Haoran Qiu; Kai Chen; Yang Yu; Ziyin Song; Jingzheng Liu; Lvyin Luo; Xinlong Ma; Zhaoyang Yuan; Maogui Li; Jianfeng Zhuang; Mingxiang Zhang; Wandong Su; Yunyan Wang; Donghai Wang; Weiying Zhong

CNS Neuroscience & Therapeutics · 2025

* Correspondence:
Weiying Zhong (zhongweiying123@163.com)
© 2025 The Author(s). CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Natural Science Foundation of Shandong Province10.13039/501100007129 ZR2022MH131

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:03:52.184999+00:00

DOI: 10.1111/cns.70617 · PMC12481830